Bausch Health Companies Inc. (NYSE:BHC) Shares Purchased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC raised its position in Bausch Health Companies Inc. (NYSE:BHC) by 283.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,918 shares of the company’s stock after purchasing an additional 5,112 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Bausch Health Companies were worth $55,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Commonwealth Equity Services LLC increased its position in shares of Bausch Health Companies by 16.3% during the 3rd quarter. Commonwealth Equity Services LLC now owns 45,699 shares of the company’s stock worth $376,000 after purchasing an additional 6,399 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Bausch Health Companies by 15.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 56,783 shares of the company’s stock valued at $470,000 after acquiring an additional 7,465 shares during the last quarter. Mackenzie Financial Corp raised its stake in shares of Bausch Health Companies by 8.1% in the 3rd quarter. Mackenzie Financial Corp now owns 1,231,232 shares of the company’s stock valued at $9,869,000 after acquiring an additional 92,515 shares during the period. Park Avenue Securities LLC acquired a new position in shares of Bausch Health Companies in the 3rd quarter worth approximately $169,000. Finally, TD Asset Management Inc boosted its position in shares of Bausch Health Companies by 17.5% during the 3rd quarter. TD Asset Management Inc now owns 1,137,247 shares of the company’s stock worth $9,421,000 after purchasing an additional 169,531 shares during the period. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BHC. Jefferies Financial Group decreased their target price on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, February 20th. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Wednesday, February 7th. Royal Bank of Canada cut their target price on shares of Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating on the stock in a research note on Tuesday, April 23rd. Finally, Piper Sandler raised their price target on shares of Bausch Health Companies from $7.00 to $9.00 and gave the company a “neutral” rating in a research report on Monday. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Bausch Health Companies currently has a consensus rating of “Hold” and a consensus price target of $11.33.

Bausch Health Companies Price Performance

Shares of NYSE:BHC traded up $0.18 during trading on Monday, hitting $8.89. 2,665,216 shares of the company were exchanged, compared to its average volume of 2,782,024. The firm’s 50 day moving average price is $9.30 and its 200-day moving average price is $8.18. The stock has a market capitalization of $3.25 billion, a P/E ratio of -5.43 and a beta of 0.85. Bausch Health Companies Inc. has a 12-month low of $5.57 and a 12-month high of $11.46.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.14. The firm had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. The firm’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.02 EPS. As a group, equities research analysts anticipate that Bausch Health Companies Inc. will post 3.95 EPS for the current year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.